INmune Bio Surges to 162nd in Trading Volume Despite 15.37% Stock Decline

On June 27, 2025, INmune Bio (INMB) experienced a significant surge in trading volume, with a turnover of $52 million, marking a 924.25% increase from the previous day. This surge placed INmune Bio at the 162nd position in terms of trading volume for the day. However, despite the high trading volume, the stock price of INmune Bio declined by 15.37%, marking the second consecutive day of decline, with a total decrease of 27.88% over the past two days.

INmune Bio announced a $19 million registered direct offering on June 27, 2025. This strategic move is aimed at fueling the company's ongoing research and development efforts, particularly in the field of Alzheimer's disease. The offering is seen as a pivotal moment for the clinical-stage biotech firm, as it seeks to advance its pipeline and potentially bring groundbreaking treatments to market.

INmune Bio's stock price experienced a notable drop following the announcement of its $19 million direct stock offering. The decline in share price was attributed to investor reactions to the equity offering, which often dilutes existing shares and can lead to a temporary decrease in stock value. Despite the short-term impact, the offering is expected to provide the necessary capital for INmune Bio to continue its innovative work in the biotechnology sector.

Trading in INmune Bio's shares was temporarily halted due to volatility following the announcement of the direct stock offering. This halt was implemented to allow for the dissemination of material information to investors and to ensure a fair and orderly market. Trading resumed shortly thereafter, with investors closely monitoring the company's next moves and the potential impact on its stock price.